Latest Announcements

BSE & NSE corporate filings with AI summaries

BSECompany Update▲ PositiveResults31 Jul 2026

KFin Technologies Ltd

Please find attached Transcript of Earnings Conference Call held on July 27, 2026

KFin Technologies Ltd published the transcript of its Earnings Conference Call for Q1 FY '27, highlighting its continued growth and resilience in the face of market volatility. The company's revenue has increased manifold over the past five years, driven by geographical diversification, asset class diversification, and business process diversification. The company's performance exudes confidence for the future, despite negligible or negative mark-to-market gains in the previous quarter.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults31 Jul 2026

Clean Max Enviro Energy Solutions Limited

Press Release

Clean Max Enviro Energy Solutions Limited has announced its Q1 FY27 financial results, with revenue from operations more than doubling year-on-year to INR 832 crore, and Adjusted EBITDA growing 74% YoY to INR 494 crore. The company's contracted RE Power Sales capacity reached 6 GW as of June 30, 2026, and its total contracted portfolio stood at 6.8 GW.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults31 Jul 2026

Remi Edelstahl Tubulars Ltd

Earing Presentation as attached

Remi Edelstahl Tubulars Ltd has released its earnings presentation for Q1FY27, showcasing a revenue of ₹45.14 LAKHS and Profit After Tax of ₹3,537.17 LAKHS. The company has a strong order book of ₹114 Crs, including multiple export orders and new customer wins.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults31 Jul 2026

Narayana Hrudayalaya Ltd.

Press Release

Narayana Hrudayalaya Ltd. has announced its Q1 FY27 results, with consolidated operating revenue at ₹ 26,836 Mn (YoY growth of 78.0%) and EBITDA of ₹ 5,052 Mn (YoY growth of 40.0%).

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults31 Jul 2026

Narayana Hrudayalaya Ltd

Investor presentation for the quarter ended June 30, 2026.

Narayana Hrudayalaya Ltd has released an investor presentation for the quarter ended June 30, 2026, highlighting its operational and financial performance. The company reported a consolidated operating revenue of ₹ 26,836 Mn, a change of +78.0% YoY and +3.5% QoQ, and a consolidated EBITDA of ₹ 5,052 Mn at a margin of 18.8%. The company also provided details on its revenue mix, patient footfalls, and ICU occupied bed days.

Read more →📎 1 attachment
NSEInvestor Presentation▲ PositiveResults31 Jul 2026

CORONA Remedies Limited

Investor Presentation

CORONA Remedies Limited has released an investor presentation for Q1 FY27, highlighting its operational and financial performance, including revenue growth, improved rankings, and EU-GMP certification for its facilities.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults31 Jul 2026

Narayana Hrudayalaya Ltd

Press release for the quarter ended June 30, 2026.

Narayana Hrudayalaya Ltd has announced its Q1 FY27 results, with consolidated operating revenue at ₹ 26,836 Mn, a YoY growth of 78.0%, and EBITDA of ₹ 5,052 Mn, a YoY growth of 40.0%. The company has also highlighted various achievements in its healthcare services, including 2,137 cardiac surgeries and the operationalization of new medical equipment.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults31 Jul 2026

Corona Remedies Ltd

Analyst/Investor presentation

CORONA Remedies Ltd has released an investor presentation for Q1 FY27, highlighting its operational and financial performance, including revenue growth, improved ranking in the IPM, and EU-GMP certification for its Oral Solid Dosage facility.

Read more →📎 1 attachment
NSEInvestor Presentation▲ PositiveResults31 Jul 2026

Narayana Hrudayalaya Ltd.

Investor Presentation

Narayana Hrudayalaya Ltd. has released its investor presentation for Q1 FY27, highlighting its operational and financial performance. The company reported a 78.0% YoY increase in consolidated operating revenues to ₹ 26,836 Mn and a 18.8% EBITDA margin. Narayana Health has expanded its footprint with new facilities and services, including robotic surgery capabilities.

Read more →📎 1 attachment
BSEBoard Meeting▲ PositiveResults31 Jul 2026

Aarti Drugs Ltd

Financial Results for the quarter ended June 30, 2026

Aarti Drugs Ltd announced its audited standalone and consolidated financial results for the quarter ended June 30, 2026, with a profit before exceptional items and tax of ₹6,994. The company reported a revenue from operations of ₹70,278 and a total income of ₹72,030. The financial results were approved by the Board of Directors in their meeting held on July 31, 2026.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults31 Jul 2026

Glenmark Pharmaceuticals Ltd

Investor Presentation - Q1 FY 26-27

Glenmark Pharmaceuticals Ltd has reported Q1 FY27 results with consolidated revenue of Rs. 40,185 million, a 23.1% YoY growth, driven by broad-based growth across key markets, with India, North America, and Emerging Markets delivering strong performance.

Read more →📎 1 attachment
NSEUpdates▲ PositiveResults31 Jul 2026

Glenmark Pharmaceuticals Limited

Updates

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Investor Presentation' for Q1 FY 27, with consolidated revenue of Rs. 40,185 million, a 23.1% YoY growth, and EBITDA of Rs. 8,048 million with a margin of 20.03%. The company has reported strong growth across its key markets, with India business growth of 15.5%, North America core business growth of 19.8%, and Emerging Markets business growth of 27.7%. The results reinforce the direction of Glenmark's next phase: strengthening its core businesses while expanding its differentiated specialty and innovation-led platforms.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults31 Jul 2026

Glenmark Pharmaceuticals Limited

Press Release

Glenmark Pharmaceuticals Limited has announced its Q1 FY27 results, with consolidated revenue growing 23.1% YoY to Rs. 40,185 million, driven by strong execution and resilience of its business. The company reported EBITDA of Rs. 8,048 million, a 38.6% YoY growth, and PAT of Rs. 4,828 million, with a PAT margin of 11.8%. The company's India formulations revenue grew 15.5% YoY, North America revenue grew 41.1% YoY, and Emerging Markets revenue grew 27.7% YoY.

Read more →📎 1 attachment
BSECompany Update▲ PositiveResults31 Jul 2026

Glenmark Pharmaceuticals Ltd

Please find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30, 2026

Glenmark Pharmaceuticals Ltd has announced its Q1 FY27 results, with consolidated revenue growing 23.1% YoY to Rs. 40,185 million, driven by strong growth in India, North America, and Emerging Markets. EBITDA was Rs. 8,048 million, with a margin of 20.03%, and PAT was Rs. 4,828 million, with a margin of 11.8%. The company has also highlighted its focus on strengthening its core businesses and expanding its specialty and innovation-led platforms.

Read more →📎 1 attachment
NSEOutcome of Board Meeting▲ PositiveResults31 Jul 2026

Blue Dart Express Limited

Outcome of Board Meeting

Blue Dart Express Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors. The results include a net profit of ₹8,668 and a dividend of ₹25 per equity share for the financial year ended March 31, 2026.

Read more →📎 1 attachment
BSECompany Update▲ PositiveOrder Win31 Jul 2026

Powerica Ltd

Execution of Power Purchase Agreement

Powerica Ltd has executed a Power Purchase Agreement with Gujarat Urja Vikas Nigam Limited to set up a 100 MW Wind power project in Gujarat at a tariff of Rs. 3.435 per kWh for 25 years.

Read more →📎 1 attachment
NSEBagging/Receiving of orders/contracts▲ PositiveOrder Win31 Jul 2026

Powerica Limited

Bagging/Receiving of orders/contracts

Powerica Limited has executed a Power Purchase Agreement with Gujarat Urja Vikas Nigam Limited to set up a 100 MW Wind power project in Gujarat at a tariff of Rs. 3.435 per kWh for 25 years.

Read more →📎 1 attachment
NSEPress Release▲ PositiveResults31 Jul 2026

Yasho Industries Limited

Press Release

Yasho Industries Limited has announced its unaudited financial results for Q1 FY27, with revenue of ₹307.74Cr, a 42% YoY increase, driven by additional off-take by existing customers and acquisition of marquee international customers. EBITDA margin improved to 24.2% and PAT margin to 11.7%, driven by optimized product mix, cost discipline, and operating efficiencies.

Read more →📎 1 attachment
← PreviousPage 789 of 995Next →